Vascular Biogenics Ltd, an Israeli-American biopharmaceutical firm, is dedicated to developing cutting-edge therapeutics for the treatment of major types of cancer and immune-inflammatory diseases. Among its innovative projects is VB-601, which employs monocyte targeting technology to tackle multiple inflammatory indications. Founded in 2000 under the name of Medicard Ltd, the company rebranded as Vascular Biogenics Ltd in January 2003. From its headquarters in Modi'in, Israel, Vascular Biogenics Ltd is poised to revolutionize the biopharmaceutical industry.